Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 13 February 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) released new draft guidance documents on 13 February covering rifaximin tablets, nitroglycerin metered spray/sublingual products and nitroglycerin metered aerosol/sublingual products.
The draft guidances cover bioequivalence (BE) recommendations for both nitroglycerin and rifaximin products, particularly BE testing used to support Abbreviated New Drug Applications (ANDAs).
The draft guidances for nitroglycerin products are "revised versions of previously published draft guidances on the subject," while the rifaximin guidance is brand new.
Comments on the draftguidances are due before 13 April, 2012.
Tags: BE, Rifaximin, Nitroglycerin, ANDA, Latest News, bioequivalence, draft guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.